John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
MENLO PARK, Calif., Feb. 17, 2016 -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the fourth quarter and year ended December 31, 2015, on Thursday, February 25, 2016, after the market close. Geron’s management will also host a conference call for analysts and investors on Thursday, February 25, 2016, at 4:30 p.m. Eastern Time to discuss the company’s fourth quarter and annual results and events.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 48851221. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at http://edge.media-server.com/m/p/txcpdjvg. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through March 26, 2016.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
